Literature DB >> 22417301

MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop.

Tobias Sinnberg1, Birgit Sauer, Per Holm, Barbara Spangler, Silke Kuphal, Anja Bosserhoff, Birgit Schittek.   

Abstract

Y-box binding protein 1 (YB-1) is an oncogenic transcription and translation factor and is overexpressed in several types of cancer. Our previous data showed that YB-1 is upregulated and translocated to the nucleus during melanoma progression and that YB-1 is an important transcription factor regulating proliferation, survival, migration, invasion and chemosensitivity of melanoma cells. It has been suggested that YB-1 is activated and translocated to the nucleus after S102-phosphorylation in the DNA binding domain. In this study, we show that activation of YB-1 by S102-phosphorylation and nuclear translocation is increased during melanoma progression using a human tissue microarray with 100 melanocytic lesions. Furthermore, we analysed the mechanisms governing the expression and activity of YB-1 in melanoma cells. We show that the PI3K/AKT and p53 signalling, growth factors and chemotherapeutic agents increase YB-1 promoter activity. This, however, resulted in no or only modest increase in YB-1 protein expression. We show that the MAPK and PI3K/AKT signalling pathways, both activated in melanoma cells, as well as p53 overexpression increase YB-1 S102-phosphorylation, whereas NFκB signalling inhibits phosphorylation. Overexpression of YB-1 in melanoma cells inhibits translation efficiency and by this proliferation and survival of melanoma cells indicating that there is an autoregulatory loop restricting YB-1 protein expression. These data suggest that there is a tightly regulated feedback mechanism regulating YB-1 expression and activation, necessary for proper cell cycle progression of melanoma cells.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22417301     DOI: 10.1111/j.1600-0625.2012.01448.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  27 in total

1.  Translation regulation in skin cancer from a tRNA point of view.

Authors:  Katerina Grafanaki; Dimitrios Anastasakis; George Kyriakopoulos; Ilias Skeparnias; Sophia Georgiou; Constantinos Stathopoulos
Journal:  Epigenomics       Date:  2018-12-19       Impact factor: 4.778

2.  Insulin Directs Dichotomous Translational Regulation to Control Human Pluripotent Stem Cell Survival, Proliferation and Pluripotency.

Authors:  Xiaoxiao Zhou; Zhili Ren; Jiaqi Xu; Chunhao Deng; Zhaoying Zhang; Carlos Godoy-Parejo; Faxiang Xu; Esther Chi Cheng Huang; Jiajia Wang; Zheyu Cai; Weiwei Liu; Guang Hu; Guokai Chen
Journal:  Int J Biol Sci       Date:  2022-05-16       Impact factor: 10.750

3.  Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression.

Authors:  Sun-Hee Kim; Yuuri Hashimoto; Sung-Nam Cho; Jason Roszik; Denái R Milton; Fulya Dal; Sangwon F Kim; David G Menter; Peiying Yang; Suhendan Ekmekcioglu; Elizabeth A Grimm
Journal:  Pigment Cell Melanoma Res       Date:  2016-03-15       Impact factor: 4.693

4.  Calcineurin-mediated YB-1 dephosphorylation regulates CCL5 expression during monocyte differentiation.

Authors:  Christina Alidousty; Thomas Rauen; Lydia Hanssen; Qiang Wang; Setareh Alampour-Rajabi; Peter R Mertens; Jürgen Bernhagen; Jürgen Floege; Tammo Ostendorf; Ute Raffetseder
Journal:  J Biol Chem       Date:  2014-06-19       Impact factor: 5.157

5.  The role of Interleukin Receptor Associated Kinase (IRAK)-M in regulation of myofibroblast phenotype in vitro, and in an experimental model of non-reperfused myocardial infarction.

Authors:  Amit Saxena; Arti V Shinde; Zaffar Haque; Yi-Jin Wu; Wei Chen; Ya Su; Nikolaos G Frangogiannis
Journal:  J Mol Cell Cardiol       Date:  2015-11-02       Impact factor: 5.000

6.  High prevalence of Y-box protein-1/p18 fragment in plasma of patients with malignancies of different origin.

Authors:  Frank Tacke; Oliver Galm; Nicolas Kanig; Eray Yagmur; Sabine Brandt; Jonathan A Lindquist; Christiane S Eberhardt; Ute Raffetseder; Peter R Mertens
Journal:  BMC Cancer       Date:  2014-01-20       Impact factor: 4.430

7.  Experimental characterization of the human non-sequence-specific nucleic acid interactome.

Authors:  Gerhard Dürnberger; Tilmann Bürckstümmer; Kilian Huber; Roberto Giambruno; Tobias Doerks; Evren Karayel; Thomas R Burkard; Ines Kaupe; André C Müller; Andreas Schönegger; Gerhard F Ecker; Hans Lohninger; Peer Bork; Keiryn L Bennett; Giulio Superti-Furga; Jacques Colinge
Journal:  Genome Biol       Date:  2013-07-31       Impact factor: 13.583

Review 8.  A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance.

Authors:  Akram Alkrekshi; Wei Wang; Priyanka Shailendra Rana; Vesna Markovic; Khalid Sossey-Alaoui
Journal:  Cell Signal       Date:  2021-07-03       Impact factor: 4.850

9.  The 5'-untranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding.

Authors:  Alessandra Bisio; Elisa Latorre; Virginia Andreotti; Brigitte Bressac-de Paillerets; Mark Harland; Giovanna Bianchi Scarra; Paola Ghiorzo; Robert C Spitale; Alessandro Provenzani; Alberto Inga
Journal:  Oncotarget       Date:  2015-11-24

10.  A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.

Authors:  Azadeh Cheraghchi-Bashi; Christine A Parker; Ed Curry; Jean-Frederic Salazar; Hatice Gungor; Azeem Saleem; Paula Cunnea; Nona Rama; Cristian Salinas; Gordon B Mills; Shannon R Morris; Rakesh Kumar; Hani Gabra; Euan A Stronach
Journal:  Oncotarget       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.